Handelsbanken Fonder AB Raises Stake in Halozyme Therapeutics, Inc. $HALO

Handelsbanken Fonder AB grew its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 52.4% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 591,869 shares of the biopharmaceutical company’s stock after purchasing an additional 203,500 shares during the period. Handelsbanken Fonder AB’s holdings in Halozyme Therapeutics were worth $39,833,000 at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of HALO. Root Financial Partners LLC purchased a new stake in Halozyme Therapeutics in the 3rd quarter worth approximately $25,000. Larson Financial Group LLC boosted its position in Halozyme Therapeutics by 3,118.2% in the 3rd quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 343 shares in the last quarter. Clearstead Advisors LLC boosted its position in Halozyme Therapeutics by 107.7% in the 3rd quarter. Clearstead Advisors LLC now owns 511 shares of the biopharmaceutical company’s stock worth $37,000 after purchasing an additional 265 shares in the last quarter. Penserra Capital Management LLC purchased a new stake in Halozyme Therapeutics in the 3rd quarter worth approximately $52,000. Finally, Wexford Capital LP purchased a new stake in Halozyme Therapeutics in the 3rd quarter worth approximately $70,000. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Insider Activity at Halozyme Therapeutics

In related news, CEO Helen Torley sold 20,000 shares of the stock in a transaction on Thursday, April 2nd. The stock was sold at an average price of $64.24, for a total value of $1,284,800.00. Following the completion of the transaction, the chief executive officer directly owned 767,780 shares of the company’s stock, valued at approximately $49,322,187.20. This represents a 2.54% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,625 shares of the stock in a transaction on Friday, May 1st. The shares were sold at an average price of $63.48, for a total value of $103,155.00. Following the completion of the transaction, the director directly owned 38,498 shares of the company’s stock, valued at approximately $2,443,853.04. This represents a 4.05% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 120,482 shares of company stock valued at $8,200,842. 2.50% of the stock is owned by insiders.

Halozyme Therapeutics Trading Up 1.9%

Shares of NASDAQ:HALO opened at $68.73 on Wednesday. Halozyme Therapeutics, Inc. has a 1 year low of $51.06 and a 1 year high of $82.22. The firm has a market capitalization of $8.15 billion, a price-to-earnings ratio of 24.72, a price-to-earnings-growth ratio of 0.28 and a beta of 0.89. The company has a debt-to-equity ratio of 8.81, a current ratio of 2.76 and a quick ratio of 2.33. The business’s 50 day moving average price is $65.67 and its 200-day moving average price is $68.70.

Halozyme Therapeutics (NASDAQ:HALO) last announced its earnings results on Monday, May 11th. The biopharmaceutical company reported $1.60 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.54 by $0.06. Halozyme Therapeutics had a return on equity of 187.91% and a net margin of 23.13%.The firm had revenue of $376.71 million for the quarter, compared to analyst estimates of $358.60 million. During the same quarter last year, the firm posted $1.11 EPS. The business’s revenue was up 42.2% on a year-over-year basis. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. On average, equities research analysts forecast that Halozyme Therapeutics, Inc. will post 7.66 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on HALO shares. HC Wainwright upped their price objective on Halozyme Therapeutics from $90.00 to $95.00 and gave the stock a “buy” rating in a research report on Wednesday, April 29th. Weiss Ratings upgraded Halozyme Therapeutics from a “hold (c)” rating to a “buy (b-)” rating in a research report on Tuesday, May 12th. TD Cowen restated a “buy” rating on shares of Halozyme Therapeutics in a research report on Wednesday, February 18th. Wall Street Zen upgraded Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday. Finally, Wells Fargo & Company increased their target price on Halozyme Therapeutics from $65.00 to $75.00 and gave the company an “equal weight” rating in a research report on Thursday, February 19th. Seven investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $80.67.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.